The main goal of the trial is to learn how safe the medicine is and how well patients can tolerate increasing doses. Participants will receive the drug in a series of treatment cycles that last about four weeks each, with the amount of medicine gradually increased in early groups to find the highest dose that can be given without unacceptable side effects.

During the study, patients will have regular check‑ups, blood tests, and scans to watch for any side effects and to see how the cancer responds. Any problems that arise will be recorded and managed by the medical team, and the study will continue until the predetermined number of treatment cycles is completed or if a participant chooses to stop early.

The treatment involves the intravenous administration of SGN-ALPV, meaning the medicine is delivered directly into a vein through a needle or tube. Participants in the study will receive the drug in different amounts to help researchers determine the highest dose that can be given safely without causing too many side effects. During the study, medical professionals will monitor how the body reacts to the medication and how much of the drug remains in the bloodstream over time.

The treatments being studied include belzutifan, which is taken as an oral film-coated tablet, and lenvatinib, which is taken as an oral capsule. Participants in the study will continue their current treatment regimen to monitor how the medications work over a longer period of time. The study will track overall survival, which refers to the length of time patients remain alive, and monitor any adverse events, which are side effects or unexpected medical problems that may occur during the treatment.

The main goal of this study is to find out how well inavolisib works in treating endometrial cancer that has the PIK3CA mutation. The researchers will measure this by looking at how many patients have their tumors shrink or disappear completely. The study will also look at other things such as how long patients live without their cancer getting worse, how long the response to treatment lasts, and whether the treatment works differently depending on which specific PIK3CA mutation a patient has or whether their PTEN gene is working normally. The safety of the medicine will also be carefully monitored throughout the study.

Patients will take inavolisib as a film-coated tablet by mouth. Before starting treatment, patients will need to provide a tissue sample from their cancer and blood samples for testing to confirm they have the PIK3CA mutation and to check the PTEN gene status. During the study, blood samples will be collected to track changes in the cancer. The treatment will continue as long as it is helping and not causing unacceptable side effects. Patients will be followed to see how their cancer responds to the treatment using imaging scans and other assessments.

Patients in this study will receive zanidatamab on its own, without combining it with other cancer treatments. The medicine will be given regularly over a treatment period that can last up to 60 weeks. The doctors will check how the tumors respond to the treatment by doing regular scans and tests. Some patients in the study may have breast cancer or cancers of the stomach and food pipe area, and they may have received a specific type of HER2-targeted therapy before, which is a treatment that works against the HER2 protein. For other types of solid tumors, patients should not have had this type of treatment before.

During the study, doctors will monitor patients carefully to see if the treatment is working and to watch for any side effects. This includes checking heart function, blood tests to see how the liver and kidneys are working, and measuring the size of the tumors. Patients will also be asked about symptoms they experience using questionnaires. The study will look at how many patients see their tumors shrink, how long the treatment keeps working, and how long patients live. Blood samples will be taken to measure the amount of medicine in the body and to check if the body makes any reaction against the medicine.

In this study, participants will receive either rinatabart sesutecan or a treatment selected by their doctor, which may include medications such as doxorubicin or paclitaxel. These medications are administered through an IV infusion, a method where medicine is delivered directly into a vein through a small tube. The study aims to determine if the new drug works better than the standard options currently available for this condition.

During the course of the study, participants will undergo regular monitoring to track how the cancer responds to the medication and to observe any side effects. The researchers will look at how long the cancer remains stable without growing and the overall survival of the participants. This process involves continuous observation over several years to collect data on how the treatments affect the health and well-being of the individuals involved.

During the study, participants receive these medications to see how well they work against the tumor. The progress of the disease is monitored using imaging tools such as a computed tomography scan or an MRI, which are special types of pictures taken of the inside of the body. These tools help to determine if the cancer is shrinking or staying the same.

The study has two main parts. The first part aims to find the right dose of ubamatamab when given alone or with cemiplimab by checking how safe it is and how the body processes the medication. The second part looks at how well these treatments work in shrinking or controlling the cancer. For patients with ovarian, fallopian tube, or primary peritoneal cancer, they must have received at least one previous treatment with platinum-based chemotherapy and have cancer that has returned or is no longer responding to treatment. For patients with endometrial cancer, they must have previously received treatment with a type of immune therapy and platinum-based chemotherapy, and their cancer must show a certain protein marker called MUC16 in at least one quarter of the tumor cells.

During the study, patients will receive their assigned treatment and be monitored regularly for side effects and to see how their cancer responds. Doctors will use scans and blood tests to check if the cancer is shrinking, staying the same, or growing. The study will also measure how the treatment affects quality of life and daily functioning through questionnaires. Blood samples will be taken to measure the amount of medication in the body and to check if the body develops any reaction to the medications. The study will continue until enough information is gathered about the safety and effectiveness of these treatments.

The purpose of this study is to compare how the body absorbs different versions of Lenvatinib 10 mg capsules, including two test products and one reference product, when taken both with and without food. The study will measure how much of the medication enters the bloodstream and how long it stays in the body. This is done by looking at the highest level of medication in the blood, when this highest level occurs, and the total amount of medication in the blood over time. The study will also evaluate safety by monitoring any unwanted effects, heart activity through electrical recordings, vital signs like blood pressure and heart rate, and laboratory test results.

The study involves healthy volunteers who will receive single doses of the medication in different treatment periods. Participants will take each version of the capsule at different times, with breaks between treatments, to allow comparison of how each version works in the body. The study design allows each person to receive all three treatments in a specific order, with some participants taking the medication without food and others taking it with food. Blood samples will be collected to measure the levels of medication, and participants will be monitored throughout the study for any changes in their health.

The study is divided into different parts. In the first parts, called Part A, Part B, and Part C, researchers will test different doses of the drug to find out which dose is safe and works best. They will carefully watch for any side effects and see how the body processes the drug. In Part D, the study will focus specifically on people with pancreatic adenocarcinoma and will look more closely at whether the drug helps shrink tumors or stop them from growing. During the study, participants will receive the study drug and will have regular check-ups to monitor their health and see how the cancer is responding to treatment.

Throughout all parts of the study, doctors will measure how much of the drug is in the blood, watch for any unwanted effects, and check if the cancer gets better, stays the same, or gets worse. They will also test whether the body develops an immune response to the drug over time. The study will track how long any positive effects last and whether people need to stop treatment or change their dose because of side effects. All participants must have already tried standard treatments that are normally used for their type of cancer, and those treatments must not have worked well enough or must no longer be available as an option.

The purpose of the study is to compare how well BNT323 works against the doctor’s choice of chemotherapy in stopping the cancer from getting worse or spreading. The study will measure how long patients live without their cancer growing or spreading, and how long patients survive overall. The study will also look at how many patients have their tumors shrink or disappear, how long these responses last, and what side effects occur with each treatment. Patients will be assigned to one treatment or the other by chance, similar to flipping a coin, and both the patients and their doctors will know which treatment is being given.

During the study, patients will receive their assigned treatment for up to six months, and they will be monitored regularly with scans and tests to see how their cancer is responding and to check for any side effects. The study will track whether the cancer grows or spreads, and doctors will use specific measurement criteria to evaluate the size and extent of the tumors throughout the treatment period. The information gathered will help determine whether BNT323 is more effective than standard chemotherapy for treating this type of recurring uterine cancer.

The purpose of this research is to evaluate how well dostarlimab works when given before surgery (as neoadjuvant therapy) in treating this specific type of endometrial cancer. During the study, participants will receive dostarlimab infusions, with each dose being 500 mg. The treatment may continue for up to 66 weeks, with regular medical check-ups to monitor the patient’s condition.

Throughout the study, doctors will use various imaging tests such as MRI, CT scan, and PET scan to check how the cancer responds to treatment. They will also perform physical examinations and monitor for any side effects. The total amount of dostarlimab that a patient might receive during the entire study period could reach up to 12,000 mg.

The study will test MK-5684 alongside several other medications that may be used as standard treatments, including tamoxifen, exemestane, letrozole, fulvestrant, megestrol, and medroxyprogesterone. Some participants may also receive medications to manage side effects, such as dexamethasone, hydrocortisone, and fludrocortisone.

During the study, participants will receive either MK-5684 or standard treatment medications. The study will track how long participants live without their cancer getting worse, their overall survival time, and how well they respond to treatment. Doctors will monitor participants for any side effects throughout the treatment period, which may last up to 60 months.

Endometrial cancer is a cancer that begins in the lining of the uterus (the endometrium). In this study, participants will be randomly assigned to receive one of three treatment combinations. Some will receive trastuzumab deruxtecan with rilvegostomig, others will receive trastuzumab deruxtecan with pembrolizumab, and a third group will receive the standard chemotherapy with pembrolizumab. Trastuzumab deruxtecan is a medication that targets cancer cells with high levels of a protein called HER2. Pembrolizumab and rilvegostomig are types of immunotherapy medications that help the immune system recognize and attack cancer cells.

Throughout the study, participants will undergo regular evaluations to monitor how their cancer responds to treatment and to check for any side effects. These evaluations will include imaging tests to measure tumors and laboratory tests to assess organ function and overall health. The study will track how long participants remain without their cancer getting worse and their overall survival time.

The purpose of the study is to compare these treatments to see which is more effective in maintaining the health of participants with advanced or recurrent endometrial cancer. Participants will receive either the combination of sacituzumab tirumotecan and pembrolizumab or pembrolizumab alone. The study will monitor the participants’ health over time to assess the progression of the disease and overall survival rates.

Throughout the study, participants will be regularly evaluated to track their response to the treatment. This includes monitoring for any side effects and changes in their quality of life. The study aims to provide valuable information on the best treatment approach for individuals with this type of endometrial cancer.

The purpose of this study is to evaluate how effective this combination of medications is in treating the specified types of cancer. Participants in the study will receive these medications and will be monitored over time to assess their response to the treatment. The study will track the progression of the disease and any changes in the participants’ health. The trial aims to gather information on how well the treatment works and any side effects that may occur.

Throughout the study, participants will undergo regular check-ups and assessments to monitor their health and the impact of the treatment. The study is designed to provide valuable insights into the potential benefits and risks of using relacorilant in combination with nab-paclitaxel and bevacizumab for treating these advanced cancers. This research could contribute to developing more effective treatment options for patients with these types of cancer in the future.

The purpose of the study is to assess how well Raludotatug Deruxtecan works in treating these cancers and to monitor any side effects. Participants in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will follow participants over a period to observe the treatment’s impact on their cancer and overall health.

Throughout the trial, researchers will focus on understanding how the treatment affects the size and growth of the tumors, as well as any changes in the participants’ health. The study aims to provide valuable information on the potential benefits and risks of using Raludotatug Deruxtecan for these types of cancers, contributing to future treatment options for patients with advanced or metastatic solid tumors.

The purpose of the study is to learn more about how well the treatment works and how safe it is for participants. The study will involve taking the medication by mouth for a period of up to 36 months. Participants will be monitored regularly to see how their tumors respond to the treatment and to check for any side effects. The study will also look at how long the treatment keeps the disease under control and how it affects the overall health and quality of life of the participants.

Participants in the study will have regular check-ups and tests to track their progress. These tests will help researchers understand the effectiveness of the treatment and any potential risks. The study aims to provide valuable information that could lead to better treatment options for people with these types of tumors in the future.

Participants in the study will receive the treatment as a solution for infusion, which means it will be given through a vein. The study will observe how the treatment affects the cancer and monitor any side effects. The trial will include regular check-ups and assessments to track the progress of the treatment. The study aims to understand how well the treatment works in shrinking the tumors and how safe it is for the patients.

The study will continue for several years, with the goal of gathering enough information to determine the treatment’s effectiveness and safety. This research is important for developing new ways to treat these challenging cancers and could potentially lead to new treatment options for patients in the future.

The medication being tested, fadraciclib, is taken by mouth in tablet form. It belongs to a group of drugs called CDK2/9 inhibitors, which work by blocking certain proteins that help cancer cells grow. The study aims to find the best dose of the medication and determine how well it works in treating these different types of cancer.

During the study, participants take the medication either once or twice daily in 28-day cycles. The treatment continues as long as it is helping and the side effects are manageable. Throughout the study, doctors monitor the participants’ health and how their cancer responds to the treatment. This includes regular check-ups and various medical tests to ensure safety and track the effectiveness of the medication.

Participants in the study will receive one of several treatments, which include Patent Blue, Technetium (99mTc) Rheniumsulfide Colloid, Indocyanine Green, and Technetium (99mTc) Nanocolloid. These substances are used to help identify the lymph nodes that need to be examined. The study will look at how these treatments affect the body during and after surgery, focusing on any complications that might occur. The goal is to see if the sentinel node policy can reduce the risk of complications compared to the standard approach.

The trial will follow participants for up to three years after their surgery to monitor for any complications and to see how well the cancer is controlled. This includes checking for any signs of the cancer returning and assessing the overall health and survival of the participants. The study aims to provide valuable information that could improve the way early-stage endometrial cancer is treated in the future.

The purpose of this study is to continue providing treatment to patients who have completed a previous cancer study with Olaparib and are still benefiting from it. The study aims to ensure the safety and tolerability of the ongoing treatment. Patients will continue to receive Olaparib if they are judged by their doctor to be benefiting from the treatment. The study will monitor the patients’ health and any side effects that may occur during the treatment period.

Participants in this study will take Olaparib tablets orally, with the treatment period lasting up to 123 days. The study will keep track of any serious side effects or important medical events that happen up to 30 days after the last dose of the study drug. This trial is designed to help patients who are already experiencing positive effects from Olaparib to continue their treatment safely.

Participants in the study will receive a combination of these treatments. Initially, they will be given Paclitaxel and Carboplatin along with Durvalumab. After this initial phase, some participants will continue to receive Durvalumab alone, while others will receive Durvalumab in combination with Olaparib. The study is designed to compare these different treatment approaches to see which is most effective in preventing the cancer from progressing.

The study will be conducted over a period of time, with regular monitoring to assess the health and response of the participants to the treatments. The goal is to determine how well these treatments work in extending the time patients live without their cancer getting worse and to evaluate the overall safety of the treatment combinations. Participants will be closely observed for any side effects or changes in their condition throughout the study.

Participants in the study will receive pembrolizumab over a series of 9 treatment cycles. The main goal is to see how many patients experience a significant reduction in their cancer after these cycles. This reduction is referred to as a major pathologic response, which means the cancer has shrunk significantly when examined under a microscope. The study will also look at other factors, such as how long patients remain free from cancer recurrence after treatment and the safety of using pembrolizumab in this way.

The trial aims to gather information that could lead to further research comparing this treatment approach to other standard treatments. By understanding how pembrolizumab works in this setting, researchers hope to improve treatment options for patients with mismatch repair deficient uterine cancer in the future.

The purpose of this study is to evaluate how safe and effective these drug combinations are for treating these types of cancer. The study is divided into two parts – first checking the safety of the treatment combinations, and then examining how well they work in fighting the cancer.

During the study, participants will receive their assigned treatment combination through intravenous infusion. The treatments will be given in cycles, and patients will be monitored regularly to check their response to the treatment. Doctors will use imaging scans to measure if tumors are shrinking and will track any side effects that may occur. The total treatment period may last up to 24 months, depending on how well patients respond to the treatment.

The purpose of this study is to better understand how these medications can benefit patients with these types of cancers after they have received standard first-line treatment. The study will explore the status of a condition called HRD, which stands for homologous recombination deficiency, a situation where cancer cells are less able to repair DNA damage. Participants will receive Olaparib in combination with Bevacizumab to see if this combination can provide additional benefits. The study is non-randomized and open-label, meaning all participants will know which treatment they are receiving, and it is designed to gather information prospectively, or looking forward in time.

Participants in the study will follow a treatment plan that includes taking Olaparib orally and receiving Bevacizumab through intravenous use. The study will last for a period of time, with regular monitoring to assess the effects of the treatment. The main goal is to determine how well the HRD status can be identified using different tests and to see how this status affects the treatment outcomes. The study will also look at the progression-free survival and overall survival of participants, as well as any side effects experienced during the trial. The trial is expected to continue until 2028.

The purpose of the study is to evaluate the safety and effectiveness of MORAb-202 in patients with these specific types of cancer. The study will be conducted in different phases. Initially, the focus will be on determining the safest dose of the medication. Following this, the study will further assess how well the treatment works in patients with ovarian cancer and endometrial cancer. The study will also explore different treatment schedules to find the most effective approach for patients with advanced endometrial cancer.

Participants in the study will receive the treatment through an intravenous infusion, which means the medication will be administered directly into the bloodstream. The study will monitor participants for any side effects and measure how the cancer responds to the treatment. The goal is to gather information that could lead to the development of a new treatment option for these types of cancer.

The purpose of this study is to evaluate the safety and tolerability of E7386 when used with other anticancer drugs and to determine the best dose for future studies. Participants in the trial will receive the study medications over a period of up to 26 weeks. The study will monitor how the body responds to the treatment and any side effects that may occur. Participants will take the medications orally, meaning they will swallow them, and will be regularly checked by the study team to ensure their safety and to track the progress of their treatment.

Throughout the study, researchers will collect information on how well the treatment works in controlling the cancer, including measuring the size of the tumors and checking for any signs of cancer progression. The study will also look at how long participants live after starting the treatment and how long any positive effects of the treatment last. This information will help determine if the combination of E7386 and Lenvima is a promising option for treating solid tumors in future clinical trials.

The purpose of the study is to see if Dostarlimab can help patients live longer without their cancer getting worse, which is known as progression-free survival. Participants in the study will be randomly assigned to receive either Dostarlimab or the standard chemotherapy treatment. The study will last for a period of time, during which participants will receive their assigned treatment and be monitored regularly to check on their health and the status of their cancer. The study will also look at other important outcomes, such as overall survival, quality of life, and how well the cancer responds to the treatment.

Throughout the study, participants will have regular check-ups and assessments to monitor their progress. These assessments may include imaging tests and other evaluations to see how the cancer is responding to the treatment. The study aims to provide valuable information about the potential benefits of Dostarlimab for patients with advanced or metastatic endometrial cancer, helping to improve future treatment options for this condition.

The purpose of the study is to compare the effectiveness and safety of MK-2870 with other treatments. Participants in the study will be randomly assigned to receive either MK-2870 or a treatment chosen by their doctor. The study will monitor how long participants live without their cancer getting worse and their overall survival. Participants will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will also look at how well the cancer responds to the treatment and any side effects that may occur.

Throughout the study, participants will have regular check-ups and tests to monitor their health and the progress of their cancer. These tests may include imaging scans to see how the cancer is responding to the treatment. The study aims to provide valuable information about the potential benefits and risks of MK-2870 for people with endometrial cancer who have already received other treatments. The study is expected to continue for several years to gather comprehensive data on the treatment’s effectiveness and safety.

The purpose of this study is to determine the best dose of CPI-0209 and to evaluate its effectiveness in treating these advanced cancers. The study is divided into two phases. In the first phase, researchers aim to find the maximum dose that patients can tolerate. In the second phase, the focus is on assessing how well CPI-0209 works in shrinking or controlling the tumors. Patients participating in the study will receive either CPI-0209 or a placebo, and their health will be monitored closely throughout the trial.

Participants in the study will undergo regular health assessments, including blood tests and imaging scans, to track the progress of their treatment. The study will help researchers understand the potential benefits and side effects of CPI-0209, contributing to the development of new treatment options for patients with these challenging types of cancer. The trial is expected to continue until 2025, providing valuable insights into the treatment of advanced solid tumors and lymphomas.

The purpose of the study is to evaluate how well PC14586 works in treating these specific types of tumors. Participants in the study will receive the medication and be monitored for its effects on their cancer. The study will also look at how safe and tolerable the medication is for patients, as well as how the body processes the drug. This will involve regular check-ups and assessments by healthcare professionals to ensure the well-being of the participants.

Throughout the study, participants will undergo various tests and evaluations to track the progress of their treatment. These may include imaging tests to see how the tumors respond to the medication and regular health assessments to monitor any side effects. The study aims to gather important information that could lead to new treatment options for patients with these specific types of cancer.

Participants in the study will receive Giredestrant and undergo regular assessments to monitor how the cancer responds to the treatment. The main goal is to evaluate the reduction in cancer at a 6-month check, alongside the safety of the drug. More detailed assessments will include checking the extent of cancer regression and monitoring its duration, as well as collecting blood samples to measure the amount of Giredestrant in the body at specified times.

This trial does not use a comparison group receiving a placebo, meaning all participants will be administered the active treatment. Patients will provide samples before and during the study for more comprehensive examination, including scans such as MRI or CT to monitor the presence and spread of the cancer. The information gained from this study may help in understanding how effective Giredestrant is as a therapy for this specific cancer type.

The purpose of the study is to evaluate how well Disitamab Vedotin works in treating these cancers. Participants in the study will receive the treatment as a powder mixed into a solution, which is then given through an infusion. The study will follow participants over a period of time to observe the effects of the treatment on their cancer. Some participants may receive a placebo, which is a substance with no active medication, to compare the results.

Throughout the study, researchers will monitor the participants’ health and any changes in their cancer. They will look at how the cancer responds to the treatment, any side effects that occur, and how long the effects last. The study aims to provide valuable information on the effectiveness and safety of Disitamab Vedotin for these types of cancer.

The purpose of the study is to assess the safety and tolerability of AZD9574 in patients with these advanced cancers. Participants will receive the medication in the form of a film-coated tablet taken orally. The study will monitor how the body processes the drug, its effects on the cancer, and any side effects that may occur. Some participants may receive a placebo for comparison. The study will also explore how the drug affects specific biomarkers, which are indicators of how the body is responding to the treatment.

Throughout the study, participants will undergo regular health checks, including blood tests and imaging scans, to track their progress and the impact of the treatment. The study aims to gather information over a period of time to determine the potential benefits and risks of AZD9574 for treating these types of cancers. This research is important for developing new treatment options for patients with advanced solid tumors.

The main purpose of this research is to test how safe BNT142 is and to see how well it works in treating these types of cancers. The study is divided into two parts. In the first part, different dose levels of the medication will be tested to find the most appropriate dose. The second part will look more closely at how well the treatment works in fighting the cancer.

During the study, patients will receive BNT142 treatment, and doctors will monitor their health and how their cancer responds to the medication. The treatment targets specific features of cancer cells, particularly a protein found on the surface of certain tumor cells. The study will track various measures of the treatment’s effectiveness, including whether tumors shrink or stop growing, and how long any positive effects last.

Participants in the study will receive treatments that may include paclitaxel and carboplatin, which are medications used to treat cancer. These medications are given through an intravenous infusion, meaning they are delivered directly into the bloodstream through a vein. The study will also involve a comparison with a placebo, which is a substance with no active medication, to help understand the effectiveness of the treatments. The study will last for a period of up to 18 months, during which participants will be monitored for their overall survival and recurrence-free survival, which means the length of time they live without the cancer coming back.

Throughout the study, various assessments will be conducted to evaluate the participants’ quality of life and any side effects they may experience. These assessments will include questionnaires and medical imaging tests. The study will also look at the cost-effectiveness of the treatments and any complications that may occur within 30 days after surgery. The goal is to gather information that could improve the way endometrial cancer is treated in the future.

Participants in the study will receive either the combination of pembrolizumab and lenvatinib or chemotherapy. The study will monitor how long participants live without the cancer getting worse and overall survival rates. The study will also look at the quality of life of participants and any side effects they may experience. The medications will be given in different forms: pembrolizumab is administered through an intravenous infusion, which means it is given directly into a vein, while lenvatinib is taken orally in capsule form.

The study will take place over a period of time, with regular check-ups and assessments to track the progress of the treatment. Participants will be closely monitored by healthcare professionals to ensure their safety and to gather information on how the treatments are working. The goal is to find out if the combination of pembrolizumab and lenvatinib can provide a better treatment option for people with advanced or recurrent endometrial carcinoma compared to traditional chemotherapy.

The purpose of this study is to evaluate the safety and effectiveness of these medications when used together. Participants in the study will receive the combination of these medications and will be monitored for any side effects and how their cancer responds to the treatment. The study will take place over a period of time, during which participants will have regular check-ups and assessments to track their progress. The study aims to understand how well the combination of these medications can help in treating the different types of cancer mentioned.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how the treatment affects their cancer. The study will help researchers learn more about the potential benefits and risks of using Pembrolizumab, Lenvatinib, and Belzutifan together, which could lead to new treatment options for patients with these types of cancer in the future.

The medications will be administered in different ways – some as tablets taken by mouth, while others as solutions given through intravenous infusion (delivered directly into a vein). The treatment period may continue for up to 104 weeks, depending on how well patients respond to the therapy and any side effects they may experience.

This is known as an umbrella study, which means it includes several different groups of patients who will receive different combinations of treatments based on specific characteristics of their cancer. Some patients will receive a single medication, while others may receive a combination of treatments. The study will track how the cancer responds to these treatments and monitor the overall health of the participants throughout the treatment period.